Immunoprophylaxis of leprosy continues to intrigue medical M. leprae. [10] Shepard et al. [11] have shown that BCG was most scientists even today. Due to this continuing interest, protective under two circumstances: just before the challenge in spite of the merits and demerits of bacillus Calmettewith M. leprae and just before the logarithmic multiplicative Guérin (BCG) vaccine, its routine use has been postulated phase of M. leprae in mice. Although some studies found BCG to benefit the outcome of the World Health Organization's to be more protective in leprosy than in tuberculosis, [12] a (WHO) anti-leprosy strategy. Moreover, the BCG vaccine meta-analysis of the experimental studies demonstrated an containing heat-killed M. leprae (HKML) has been shown overall protection of 26% in leprosy, which was lower than to offer some immunity against the invasion of M. leprae.
the average protection of 50% seen in tuberculosis.
[13]
Its reported efficacy ranges from 34% to 80% in different countries [1] [2] [3] across the globe. Despite the variable efficacy, META-A-ANALY YSIS OF BCG VA ACCINE DAT A A TA ANAL SIS OF BCG V CCINE D MET BCG vaccination is still widely recommended for use in leprosy-endemic countries. Nevertheless, it is still a matter A meta-analysis of data pertaining to the utility of the BCG of speculation [4] [5] [6] as to who should be vaccinated, when and vaccine in leprosy [14] has concluded that there is sufficient how often, in order to achieve optimum protection.
evidence of a protective effect of BCG vaccine against leprosy, based on data of trials, cohort studies and case-BCG VA ACCINE control studies. However, results of a similar meta-analysis BCG V CCINE done in the past by another group of workers have been Although the BCG vaccine was initially developed for less optimistic. [7] They found that in experimental studies, protection against M. tuberculosis, it was deemed to be able BCG vaccination offered an average protection of 26% to protect against M. leprae as well. The efficacy of the second (95% confidence interval (CI) 14-37%) against leprosy with dose of the BCG vaccine in the general population was found significant heterogeneity amongst the trials (P<0.00001). to differ from 0 to 50% in Brazil and Malawi respectively. [1] [2] [3] 7] However, the overall protective effect of BCG was estimated The protective efficacy of the first dose of BCG vaccine was to be 61% (95% CI 51-70%), also with significant heterogeneity found to be 14 per cent in the general population and 80 per cent in household contacts of leprosy cases in India. [3, 7] The enhancement of cell-mediated immune response following BCG vaccination was demonstrated earlier in Argentina [8] among contacts of leprosy patients. However, it was argued [9] that BCG along with killed M. leprae is a better combination in enhancing the immune response. Animal studies have also demonstrated that BCG is protective against in these observational studies (P<0.00001). [10] Thus they concluded that the observational studies overestimated the protective effect of BCG vaccine in leprosy. The protection was better for multibacillary (MB) leprosy than for paucibacillary (PB) leprosy. However, whereas the experimental studies demonstrated a protective effect of 31% for indeterminate (I) leprosy; the observational studies showed an increased risk for it. As with all meta-analyses, like the one published in this issue, [14] the optimistic findings may be influenced by three important factors-heterogeneity among studies, bias and publication bias. Some other issues not addressed in the article relevant to bias are the role of environmental and geographic factors, knowledge of immunization status of the trial participants and last but not the least, a misclassification, a major hazard of leprosy eradication and/or elimination.
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relevant and less cost-effective [1, 2, 17] although they continue to engage academic minds. Thus, on reviewing the available scientific data, we concur with the WHO view [17] that the leprosy vaccine in any form is currently not a practical alternative for the prevention of leprosy. [1] 
